These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 35600013)

  • 1. Immune-mediated thrombotic thrombocytopenic purpura in a Jehovah's Witness - Effectiveness of incorporating extracorporeal immunoadsorption to caplacizumab, steroids and rituximab.
    Cardesa-Salzmann TM; Stephan B; Simon A; Furtwängler R; Schöndorf D; Heine S; Torfah E; Lux M; Meyer S; Graf N
    Clin Case Rep; 2022 May; 10(5):e05902. PubMed ID: 35600013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic modalities in thrombotic thrombocytopenic purpura management among Jehovah's Witness patients: A review of reported cases.
    Tran MH
    Transfus Apher Sci; 2023 Aug; 62(4):103706. PubMed ID: 36990894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful management of thrombotic thrombocytopenic purpura in a Jehovah's Witness without plasma exchange.
    Chai W; Chaudhry A; Rabinowitz AP
    J Clin Apher; 2015 Feb; 30(1):46-9. PubMed ID: 24782109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival of a Jehovah's Witness with thrombotic thrombocytopenic purpura without using plasma: A case report and review of the literature.
    Baseri B; Vishwanathan S; Benasher D; Khazan M; Luhrs C; Tsai HM
    J Clin Apher; 2019 Oct; 34(5):623-630. PubMed ID: 31116457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful Management of Thrombotic Thrombocytopenic Purpura in a Jehovah's Witness: An Individualized Approach With Joint Decision-Making.
    Lim MY; Greenberg CS
    J Patient Exp; 2020 Feb; 7(1):8-11. PubMed ID: 32128364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful management of a Jehovah's Witness with thrombotic thrombocytopenic purpura unwilling to be treated with therapeutic plasma exchange.
    Dabak V; Kuriakose P; Raman S
    J Clin Apher; 2007; 22(6):330-2. PubMed ID: 18080270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Caplacizumab Without Plasma Exchange for Thrombotic Thrombocytopenic Purpura in a Jehovah's Witness.
    Spencer C; Abuhelwa Z; Beran A; Alsughayer A; Sheikh T; Oostra D; Assaly R; Hamouda DM
    Am J Ther; 2023 Sep-Oct 01; 30(5):e502-e505. PubMed ID: 37713712
    [No Abstract]   [Full Text] [Related]  

  • 8. Management of thrombotic thrombocytopenic purpura without plasma exchange: the Jehovah's Witness experience.
    George JN; Sandler SA; Stankiewicz J
    Blood Adv; 2017 Nov; 1(24):2161-2165. PubMed ID: 29296863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombotic thrombocytopenic purpura induced by trimethoprim-sulfamethoxazole in a Jehovah's Witness.
    Martin MG; Whitlatch NL; Shah B; Arepally GM
    Am J Hematol; 2007 Jul; 82(7):679-81. PubMed ID: 17266059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful use of a second course of caplacizumab in relapsed thrombotic thrombocytopenic purpura.
    Shaffer J; Grove A
    Platelets; 2022 Jul; 33(5):790-791. PubMed ID: 34565299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura.
    Goshua G; Sinha P; Hendrickson JE; Tormey C; Bendapudi PK; Lee AI
    Blood; 2021 Feb; 137(7):969-976. PubMed ID: 33280030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful management of three patients with autoimmune thrombotic thrombocytopenic purpura with paradigm-changing therapy: Caplacizumab, steroids, plasma exchange, rituximab, and intravenous immunoglobulins (CASPERI).
    Cid J; Pérez-Valencia AI; Torrente MÁ; Ávarez-Larrán A; Díaz-Ricart M; Esteve J; Lozano M
    Transfus Apher Sci; 2021 Feb; 60(1):103011. PubMed ID: 33221124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP.
    Coppo P; Bubenheim M; Azoulay E; Galicier L; Malot S; Bigé N; Poullin P; Provôt F; Martis N; Presne C; Moranne O; Benainous R; Dossier A; Seguin A; Hié M; Wynckel A; Delmas Y; Augusto JF; Perez P; Rieu V; Barbet C; Lhote F; Ulrich M; Rumpler AC; de Witte S; Krummel T; Veyradier A; Benhamou Y
    Blood; 2021 Feb; 137(6):733-742. PubMed ID: 33150928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Caplacizumab Therapy without Plasma Exchange for Acquired Thrombotic Thrombocytopenic Purpura.
    Chander DP; Loch MM; Cataland SR; George JN
    N Engl J Med; 2019 Jul; 381(1):92-94. PubMed ID: 31269374
    [No Abstract]   [Full Text] [Related]  

  • 15. Treating thrombotic thrombocytopenic purpura without plasma exchange during the COVID-19 pandemic. A case report and a brief literature review.
    Galindo-Calvillo CD; Rodríguez-Roque CS; Gómez-De León A; Tarín-Arzaga L; Gómez-Almaguer D
    Transfus Apher Sci; 2021 Jun; 60(3):103107. PubMed ID: 33714651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Refractory Auto-Immune Thrombotic Thrombocytopenic Pupura Successfully Treated With Caplacizumab.
    Mellaza C; Henry N; Fayolle PM; Mortaza S; Subra JF; Veyradier A; Coppo P; Augusto JF
    Front Med (Lausanne); 2020; 7():549931. PubMed ID: 33195299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post Approval Experience with Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura at a Single Institution.
    Logothetis CN; Patel A; Eatrides J; Jaglal M; Haider M; Visweshwar N; Laber DA
    J Clin Med; 2021 Jul; 10(15):. PubMed ID: 34362201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Caplacizumab in the successful management of cardiac involvement in thrombotic thrombocytopenic purpura.
    Mahmoud AA; Eltaher B; Hashem A
    Proc (Bayl Univ Med Cent); 2022; 35(6):832-833. PubMed ID: 36304630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Developments in the use of plasma exchange and adjunctive therapies to treat immune-mediated thrombotic thrombocytopenic purpura.
    Picod A; Coppo P
    Expert Rev Hematol; 2019 Jun; 12(6):461-471. PubMed ID: 31092093
    [No Abstract]   [Full Text] [Related]  

  • 20. To treat or not to treat: a rare case of pseudo-thrombotic thrombocytopenic purpura in a Jehovah's Witness.
    Malla M; Seetharam M
    Transfusion; 2016 Jan; 56(1):160-3. PubMed ID: 26363181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.